Labeling recommendations based on exposure-response relationships to minimize musculoskeletal related adverse reactions of a Hedgehog inhibitor.

e14121Background: On July 24, 2015, FDA approved Odomzo (sonidegib) for the treatment of patients with locally advanced basal cell carcinoma. At the recommended dose of 200mg once daily, 68% of pat...